EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Prospective validation of podoplanin expression as a diagnostic biomarker of acute promyelocytic leukemia

Camilla Maria de Alencar Saraiva, Carla Roberta Peachazepi Moraes, Bruno Kosa Lino Duarte, Gislaine Borba Oliveira, Herton Luiz Alves Sales Filho, Paula de Melo Campos, Sara Teresinha Olalla Saad, Erich Vinicius De Paula

Cytometry Part B: Clinical Cytometry · 2026-03 · 110 (2) · 128-133

DOI: 10.1002/cyto.b.22252 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Cytometry Part B: Clinical Cytometry, online erschienen am 11.09.2025. Verfasst von Camilla Maria de Alencar Saraiva und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Sciences, Universidade Estadual de Campinas (Unicamp), Campinas, Brazil. Hauptthemen laut MEDLINE: Leukemia, Promyelocytic, Acute, Membrane Glycoproteins, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundo de Apoio ao Ensino, à Pesquisa e Extensão, Universidade Estadual de Campinas, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute promyelocytic leukemia (APL) is a medical emergency that needs immediate diagnosis and treatment. Podoplanin, a transmembrane glycoprotein that binds CLEC‐2 on platelets, was recently demonstrated to be abnormally expressed in leukemic blasts in APL, as opposed to other forms of AML, in a study using thawed primary cells. This study aimed to explore and validate the diagnostic accuracy of measuring podoplanin expression by flow cytometry in the differential diagnosis of APL and other forms of acute myeloid leukemia (AML) as part of the diagnostic work‐up of all cases suspected of AML in an academic hematology center. Podoplanin expression was measured by flow cytometry in bone marrow samples obtained at disease presentation from all consecutive adult patients suspected of AML. Results from 24 APL patients were compared with those from 23 non‐APL AML patients matched by age and sex. Markedly higher PDPN expression was observed in APL patients when compared to other AML patients, with an area under the curve of 0.92 (95%CI: 0.82–1.0, p < 0.0001) for the percentage of positive cells. Combining an optimal cutoff of 7.66% for PDPN‐positive blasts and 1691 for the mean fluorescence index of PDPN expression, APL was identified with a sensitivity of 87.5% and a specificity of 100%. Moreover, PDPN expression presented a negative correlation with platelet count and fibrinogen levels. PDPN expression measured by flow cytometry can accurately differentiate between APL and other forms of AML in a real‐world clinical setting, contributing to the diagnosis of this form of acute leukemia. If confirmed in larger prospective studies, the negative association of PDPN expression with fibrinogen and platelet counts supports the concept that this biomarker can potentially contribute to the clinical characterization of APL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Promyelocytic, AcuteMembrane GlycoproteinsBiomarkers, TumorHumansMaleFemaleMiddle AgedFlow CytometryAdultAgedProspective StudiesLeukemia, Myeloid, AcuteDiagnosis, DifferentialYoung AdultSensitivity and SpecificityPodoplanin

Stichwörter der Autor:innen

Podoplaninacute promyelocytic leukemiaflow cytometry

Substanzen

Membrane GlycoproteinsPDPN protein, humanBiomarkers, TumorPodoplanin

Autor:innen und Institutionen

  • School of Medical Sciences, Universidade Estadual de Campinas (Unicamp), Campinas, Brazil.
  • Universidade Estadual de Campinas (Unicamp), Centro de Hematologia e Hemoterapia (Hemocentro - Unicamp), Campinas, Brazil.

Förderung

  • Fundo de Apoio ao Ensino, à Pesquisa e Extensão, Universidade Estadual de Campinas
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Saraiva, C. M. A., Moraes, C. R. P., Duarte, B. K. L., Oliveira, G. B., Sales Filho, H. L. A., de Melo Campos, P., Saad, S. T. O., & De Paula, E. V. (2026). Prospective validation of podoplanin expression as a diagnostic biomarker of acute promyelocytic leukemia. Cytometry Part B: Clinical Cytometry, 110(2), 128-133. https://doi.org/10.1002/cyto.b.22252

Vancouver

Saraiva CMA, Moraes CRP, Duarte BKL, Oliveira GB, Sales Filho HLA, de Melo Campos P, et al. Prospective validation of podoplanin expression as a diagnostic biomarker of acute promyelocytic leukemia. Cytometry Part B: Clinical Cytometry. 2026;110(2):128-133. doi:10.1002/cyto.b.22252

BibTeX
@article{Saraiva2026,
  author = {Saraiva, Camilla Maria de Alencar and Moraes, Carla Roberta Peachazepi and Duarte, Bruno Kosa Lino and Oliveira, Gislaine Borba and Sales Filho, Herton Luiz Alves and de Melo Campos, Paula and Saad, Sara Teresinha Olalla and De Paula, Erich Vinicius},
  title = {Prospective validation of podoplanin expression as a diagnostic biomarker of acute promyelocytic leukemia},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2026},
  volume = {110},
  number = {2},
  pages = {128--133},
  doi = {10.1002/cyto.b.22252}
}
Kostenlos starten →